IRON-DEFICIENCY ANEMIA IN PATIENTS RECEIVING ORAL ANTICOAGULANTS

Katerenchuk O. I., Haymenova G. S., Lebid V. G.

CLINICAL AND EXPERIMENTAL MEDICINE

Scentific article

During the previous two decades, novel oral anticoagulants (NOACs) (dabigatran, rivaroxaban, epicasaban, etc.) have been introduced into clinical practice. In a number of studies they proved better efficacy than warfarin. At the same time, finding the optimal balance between the achievement of a clinically effective level of anticoagulation while maintaining a low risk of bleeding is a difficult task in clinical practice. Long-term administration of NOACs in elderly patients having comorbid pathology (peptic ulcer of the stomach and / or duodenal ulcer, varicose veins of the esophagus, prostate pathology, etc.) can provoke recurring “small” bleeding, which often does not attract enough attention of the patient, remains unrecognized for a long time, but eventually leads to the development of iron deficiency and even anemia. The purpose of the study: to determine the prevalence of iron deficiency and iron deficiency anemia in patients undergoing long-term NOACs treatment, to analyze the most common origins of bleeding, to assess the rationality of the prescribed treatment. 78 patients who received treatment with warfarin, rivaroxaban or acenocoumarol were enrolled to the study. Indications for long-term treatment with NOACs were: in 65 patients – a permanent form of atrial fibrillation, 13 – post-cardiac surgery indications. The average age was 64,32±3,27 years. Men were represented by a younger agegroup (57,12±2,8 years) compared to women (67,35±4,4 years; p≤0,05). The average time of treatment with NOACs PAK was 16,7±2,1 months. Episodes of bleeding were noted in 13 patients, in almost half of the cases in the form of epistahis. During the analyzed period of NOACs treatment, the laboratory criteria for anemia was noted in 11 patients, while 3 had decreased ferritin concentration <30 ng/ml. It is noteworthy that only 4 of them had documented at least one case of bleeding. By re-examination of anemic patients was found that 5 of them suffered on gum bleeding in the course of brushing the teeth, 3 of them had recurrent microscopic hematuria due to the pathology of the prostate gland and 2 of them had petechial hemorrhages on the skin. Among 11 patients who had symptoms of anemia, only 3 received iron-medication, only 2 had evaluated hemoglobin and ferritin concentration in blood in the following. Concluded that iron deficiency syndrome and anemia are wide-spread among patients receiving treatment with NOACs, possibly, as a consequence of undiagnosed “small” bleeding events. As patients don’t pay enough attention for this bleedings, iron deficiency syndrome remains undiagnosed and patients aren’t receive adequate treatment.

oral anticoagulants, iron deficiency anemia, atrial fibrillation, treatment, iron-containing drugs

1. Katerenchuk IP, Miakinkova LO. Fibryliatsiia peredserd: suchasni aspekty diahnostyky ta likuvannia. Ohliad. Praktykuiuchyi likar. 2012;4:61-71. [in Ukrainian].
2. Eisho S, Salem NM, Hoffman JL, Koerber JM, Smythe MA. Major bleeding with apixaban in atrial fibrillation: patient characteristics, management, and outcomes. Hosp Pract (1995). 2018 Aug 9:1-5. DOI: 10.1080/21548331.2018.1506675 [Epub ahead of print].
3. Sherwood MW, Nessel CC, Hellkamp AS, Mahaffey KW, Piccini JP, Suh EY, et al. Gastrointestinal Bleeding in Patients With Atrial Fibrillation Treated With Rivaroxaban or Warfarin: ROCKET AF Trial. J Am Coll Cardiol. 2015 Dec 1;66(21):2271-81.
4. Westenbrink BD, Alings M, Granger CB, Alexander JH, Lopes RD, Hylek EM, et al. Anemia is associated with bleeding and mortality, but not stroke, in patients with atrial fibrillation: Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. Am Heart J. 2017 Mar;185:140-9.
5. Zhdan VM, Zazykina DS, Lebid VH. Aspekty praktychnoi hematolohii. Metodychni rekomendatsii. Poltava; 2010. 60 s. [in Ukrainian].
6. Hutsalenko OO, Falko VP. Osnovni hematolohichni syndromy ta symptomy u praktytsi simeinoho likaria. Simeina medytsyna. 2016;3:156-8. [in Ukrainian].
7. Katerenchuk OI. Typovi hematolohichni syndromy v kardiolohii: anemiia u patsiientiv z ishemichnoiu sertsevoiu nedostatnistiu. Visnyk problem biolohii i medytsyny. 2017;2(136):137-9. [in Ukrainian].
8. Lee WH, Hsu PC, Chu CY, Lee HH, Lee MK, Lee CS, et al. Anemia as an Independent Predictor of Adverse Cardiac Outcomes in Patients with Atrial Fibrillation. Int J Med Sci. 2015 Jul 16;12(8):618-24.
9. Keskin M, Ural D, Altay S, Argan O, Börklü EB, Kozan Ö. Iron deficiency and hematinic deficiencies in atrial fibrillation: A new insight into comorbidities. Turk Kardiyol Dern Ars. 2018 Mar;46(2):103-10.
10. Dai L, Mick SL, McCrae KR, Houghtaling PL, Sabik JF, Blackstone EH, et al. Preoperative Anemia in Cardiac Operation: Does Hemoglobin Tell the Whole Story? Ann Thorac Surg. 2018 Jan;105(1):100-7.
11. DeRemer CE, McMichael B, Young HN. Warfarin Patients With Anemia Show Trend of Out-of-Range International Normalized Ratio Frequency With Point-of-Care Testing in an Anticoagulation Clinic. J Pharm Pract. 2018 Jan 1:897190018768114. DOI: 10.1177/0897190018768114 [Epub ahead of print].
12. Tramarin R, Pistuddi V, Maresca L, Pavesi M, Castelvecchio S, Menicanti L, et al. Patterns and determinants of functional and absolute iron deficiency in patients undergoing cardiac rehabilitation following heart surgery. Eur J Prev Cardiol. 2017 May;24(8):799-807.

«Bulletin of problems biology and medicine» Issue 4 part 1 (146), 2018 year, 78-81 pages, index UDK 616.155.194.8-07-08

10.29254/2077-4214-2018-4-1-146-78-81